Synbiotic for cognitive function in adults with obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized crossover study enrolls adults aged 30–40 with obesity and mild cognitive impairment to receive a synbiotic (L. acidophilus LA-5 plus inulin) and a control treatment in alternating periods. Cognitive function will be measured with MoCA, MMSE, and M@T, while gut- and brain-related biomarkers such as fecal butyrate, Lactobacillus acidophilus, serum inflammatory cytokines, and BDNF are also explored. The crossover design allows each participant to serve as their own control, helping to compare effects between interventions. The trial aims to clarify whether the synbiotic can favorably influence cognitive measures and related biomarkers in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 30 to 40 years.
* Diagnosis of obesity for more than 10 years.
* Presence of mild cognitive impairment, evaluated using cognitive assessment scales.
* BMI ≥30 kg/m².
* Body fat percentage ≥35% in women and ≥25% in men.
* Willingness to participate and provide written informed consent.

Exclusion Criteria:

* Advanced cognitive impairment.
* Diseases associated with cognitive impairment, including Alzheimer's disease, cerebral ischemia, cerebrovascular events, severe traumatic brain injury, or motor deficits.
* Antibiotic use during the 3 months prior to treatment.
* Allergy to almonds or any component of the synbiotic or vehicle.
* Consumption of probiotics or supplements and/or frequent intake of high-fiber or fermented foods.
* Diagnosed gastrointestinal disorders, including irritable bowel syndrome or inflammatory bowel disease, that could influence study outcomes.
* Diagnosis of type 2 diabetes mellitus.

Where it's running

• Universidad Anahuac
  Huixquilucan, State of Mexico, Mexico Recruiting

Study contacts

• Study coordinator: Antonio Ibarra, PhD
• Email: jose.ibarra@anahuac.mx
• Phone: 52 5554197603

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Weight-loss drugs tirzepatide vs. semaglutide in adults with obesity

  This trial tests whether 12 weeks of tirzepatide or semaglutide have different effects on energy balance in adults with obesity but no diabetes.

  Recruiting Phase 4 McMaster University · Hamilton, Ontario · NCT07900074

• Body composition changes after starting GLP-1 therapies in adults with obesity or type 2 diabetes

  This study will follow adults with obesity and/or type 2 diabetes who are starting or adjusting a GLP-1 receptor agonist to see how their muscle and fat change over about a year.

  Recruiting at 2 sites Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Mexico City, Mexico City and 1 other locations · NCT07835360

• Digital dietary help for people on GLP-1 therapy to reach better blood sugar and weight

  This trial tests whether adding a digital dietary program (NutriSteppe) to usual care helps adults on GLP-1 medications see better blood sugar control and weight results.

  Recruiting Kazakh Academy of Nutrition · Almaty · NCT07728669

• Dramatherapy Added to Physical Activity for Obesity Care

  This trial tests whether adding dramatherapy to a standard adapted physical activity program helps adults with obesity in bariatric or medical care improve psychosocial well‑being and weight-related outcomes.

  Recruiting Universite du Littoral Cote d'Opale · Blendecques, Hauts-de-France · NCT07685483

• Sedentary-time reduction and light activity plan to boost fitness before and after bariatric surgery

  This study tests whether a structured program to reduce sitting and increase light physical activity can improve fitness and post-surgery outcomes for women planning bariatric surgery.

  Recruiting Hospital de Sao Sebastiao · Santa Maria da Feira · NCT07663942

• Genetic predictors of weight loss with GLP-1/GIP therapies in obesity

  This study tests whether a genetic risk score and specific obesity-related SNPs can predict how much weight adults with obesity will lose on semaglutide or tirzepatide.

  Recruiting National and Kapodistrian University of Athens · Athens · NCT07653412

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.